AVITA Medical (AVHHL) Cash & Equivalents (2018 - 2025)

AVITA Medical (AVHHL) has 8 years of Cash & Equivalents data on file, last reported at $10.2 million in Q4 2025.

• For the quarter ending Q4 2025, Cash & Equivalents fell 27.1% year-over-year to $10.2 million; the trailing twelve-month figure through Dec 2025 stood at $10.2 million (down 27.1% YoY), and the FY2025 full-year result was $10.2 million, down 27.1% from the prior year.
• Cash & Equivalents for Q4 2025 stood at $10.2 million, up from $8.3 million in the prior quarter.
• Across five years, Cash & Equivalents topped out at $115.1 million in Q1 2021 and bottomed at $8.3 million in Q3 2025.
• The 5-year median for Cash & Equivalents is $17.4 million (2022), against an average of $32.7 million.
• The widest annual swing landed in 2022, when Cash & Equivalents tumbled 85.58%; it then soared 192.26% in 2023.
• A 5-year view of Cash & Equivalents shows it stood at $55.7 million in 2021, then sank by 67.4% to $18.2 million in 2022, then tumbled by 37.24% to $11.4 million in 2023, then climbed by 23.25% to $14.0 million in 2024, then slipped by 27.1% to $10.2 million in 2025.
• The last three Cash & Equivalents figures came in at $10.2 million (Q4 2025), $8.3 million (Q3 2025), and $10.6 million (Q2 2025), per Business Quant data.

Peer Comparison